Project: First-of-a-kind prophylactic treatment for peanut allergy based on natural human antibodies.

Acronym	PEANUT-BETTER (Reference Number: 114710)
Duration	01/02/2021 - 01/02/2024
Project Topic	The consortium will deliver a first-of-a-kind prophylactic treatment for severe peanut allergy based on natural human antibodies. In contrast to other preventive treatments, the consortium’s IgG-based candidate will deliver passive immunity by binding to reaction-triggering peanut allergens, thus preventing the allergic response. By the end of the project, a candidate will have been validated in cutting-edge humanised mouse models and will be ready to enter final preclinical testing in 2024.
Network	Eurostars 2
Call	Eurostars Cut–off 14

Project partner

Number	Name	Role	Country
1	Mabylon AG	Coordinator	Switzerland
2	TransCure BioServices SAS	Partner	France